-
NMPA Approves SonoScape and Acoustic Life’s Intravascular Ultrasound Products
•
The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound diagnostic equipment and Acoustic Life Science Co., Ltd’s disposable intravascular ultrasound diagnostic catheter for marketing as innovative products. The two products are used together for the ultrasonic imaging inspection of coronary artery intravascular lesions. Innovative…
-
Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis
•
German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Spevigo (spesolimab) to treat generalized pustular psoriasis (GPP) in adults. Notably, the drug, previously awarded breakthrough therapy and priority review statuses in China, took a mere three months after gaining approval in the…
-
Acotec Scientific’s NEO-Skater Balloon Approved by NMPA for Intracranial Vessels
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National Medical Products Administration (NMPA) for its intracranial PTA balloon NEO-Skater, designed to improve blood flow perfusion in atherosclerotic intracranial vessels. NEO-Skater: Innovative Design and BenefitsNEO-Skater features an improved lubrication coating on the catheter platform and…
-
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
•
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early positive update from a Phase II trial underway for envafolimab, the Alphamab-discovered programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The pivotal ENVASARC trial, being conducted by Tracon in the US and UK, is…
-
Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part one of a Phase IIb clinical study for STP705, a therapeutic that combines TGF-β1/COX-2 with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing. The trial is assessing the therapy as a treatment for cutaneous squamous cell carcinoma in…
-
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
•
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase I clinical trial in Australia for its independently developed HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) in combination with Henlius’s innovative in-house anti-PD-1 mAb serplulimab. The trial is assessing the combination in treating general advanced…
-
China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China
•
China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer that will allow the former to import and distribute Pfizer’s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in mainland China from December 14, 2022, to November 30, 2023. No financial details were disclosed. Paxlovid: Indications and Market…
-
Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter
•
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its in-house developed recyclable vena cava filter, ZYLOX Octoplus, for the prevention of pulmonary embolism (PE) caused by peripheral deep vein thrombosis (DVT). Market…
-
Innovent Biologics Collaborates with LG Chem for Tigulixostat in China
•
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South Korea firm LG Chem Life Sciences, obtaining exclusive development and commercialization rights to the latter’s tigulixostat in China. Innovent Bio will pay LG Chem a USD 10 million upfront payment and is committed to USD…
-
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
•
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD 15 million, co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The proceeds will be used to leverage an innovative discovery platform and advance the company’s lead drug candidates to treat…
-
Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and Hong Kong Science & Technology Parks (HKSTP) announced a partnership to promote a biomedicine cultivation program in the HKSTP. No financial details were disclosed. Program Objectives and SupportThe program aims to attract the world’s top…
-
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
•
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s oral COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in China. The price for one box covering a single course of treatment was set at RMB 2,980 (USD 428.23). 111 later released a statement noting that the drug…
-
Biosion and ImmunoGen Collaborate on Cancer ADCs
•
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide…
-
Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
•
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into the companion diagnostics (CDx) field. No financial details were disclosed. Abcam’s Role in Life Science ResearchAbcam is a global life science company supporting customers at the forefront of life science research, and is engaged in…
-
Henlius Biotech Partners with Medilink for Global ADC Development
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining global development, manufacturing, and commercialization rights to antibody conjugate drugs (ADCs) based on the latter’s ADC technology platform, focusing on two designated, undisclosed targets. No financial details were revealed. Medilink’s ADC TechnologyMedilink Therapeutics boasts the…
-
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
•
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study for its APG-2575, alone or combined with Calquence (acalabrutinib) plus rituximab, in recurrent/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The results were released at the 64th American Society of Hematology (ASH) annual meeting this…
-
Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study
•
China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a prospective, multi-center, randomized controlled Phase II clinical study for its IBS absorbable drug-eluting coronary stent system in China. Study Design and ResultsThe study, expected to involve upwards of 40 clinical centers across the country, is…
-
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for its IMM2520, a bispecific antibody (BsAb) targeting CD47 and PD-L1 in solid tumors. Mechanism of Action and Preclinical ResultsIMM2520, featuring functional IgG1 Fc, can activate macrophages and T cells simultaneously by targeting CD47 and PD-L1…
-
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of a Phase II clinical study for its recombinant COVID-19 vaccine ReCOV in the Philippines as a sequential booster shot. The results showed that ReCOV as a sequential booster shot was superior to mRNA vaccine in…
-
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
•
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like Kinase 4 (PLK4), a critical regulator of centriole duplication, at the 64th American Society of Hematology (ASH) annual meeting. The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202…
